Showing 1731-1740 of 2314 results for "".
- ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901; DSMB Approval to Advance Dose Escalation in Phase 1b RP Trialhttps://modernod.com/news/vigeneron-announces-fda-rare-pediatric-disease-designation-for-vg901-dsmb-approval-to-advance-dose-escalation-in-phase-1b-rp-trial/2482601/ViGeneron announced two important milestones for its novel gene therapy candidate VG901 to treat patients with retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. The FDA granted Rare Pediatric Disease Designation (RPD
- RxSight Launches LAL+ and Features Multiple Doctor Presentations at ASCRShttps://modernod.com/news/rxsight-announces-commercial-launch-of-the-lal-and-features-multiple-doctor-presentations-at-ascrs/2482213/RxSight announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL and the Light Adjustable Lens+ (LAL+). The LAL+ has a modified aspheric anterior surface that creates a small cont
- New Study Shows Eylea HD with Extended 12- or 16-Week Dosing Demonstrated Noninferior Vision Gains to Standard of Care Eyleahttps://modernod.com/news/lancet-study-eylea-hd-with-extended-12-or-16-week-dosing-demonstrated-noninferior-vision-gains-to-standard-of-care-eylea/2482151/Regeneron announced The Lancet published 1-year results from the pivotal PULSAR and
- Carl Zeiss Meditec to Acquire Dutch Ophthalmic Research Center (DORC)https://modernod.com/news/carl-zeiss-meditec-to-acquire-dutch-ophthalmic-research-center-dorc/2482014/In a move to expand its position in the vitreo-retinal surgery segment and strengthen its position in the ophthalmic medical device category globally, Carl Zeiss Meditec announced it has entered into an agreement to acquire 100% of the shares in Dutch Ophthalmic Research Cente
- LKC Technologies Releases Consensus Document for Managing Diabetic Retinopathy in Optometryhttps://modernod.com/news/lkc-technologies-releases-consensus-document-for-managing-diabetic-retinopathy-in-optometry/2481825/LKC Technologies, a provider of functional testing using electroretinography (ERG), released "Modern Fundamentals of Diabetic Retinopathy Management in Optometry," a new report on diabetic retinopathy (DR) developed by an
- The FDA Does Not Approve Outlook Therapeutics' BLA for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/the-fda-does-not-approve-outlook-therapeuticss-bla-for-lytenava-for-the-treatment-of-wet-amd/2481800/Outlook Therapeutics announced the FDA has issued a complete response letter (CRL) to the company’s BLA for ONS-5010 (Lytenava), an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its s
- OneSight EssilorLuxottica Foundation Encourages Eye Doctors to Adopt a Local School and Help More Kids See Clearlyhttps://modernod.com/news/onesight-essilorluxottica-foundation-encourages-eye-doctors-to-adopt-a-local-school-and-help-more-kids-see-clearly/2481702/Good vision is a basic human right, but one in four schoolchildren
- FDA Does Not Approve Regeneron's High-Dose Aflibercepthttps://modernod.com/news/fda-does-not-approve-regenerons-high-dose-aflibercept/2481695/Citing "an ongoing review of inspection findings at a third-party filler," the FDA declined to approve Regeneron's aflibercept 8 mg for the treatment of patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR).</
- Researchers Found a Way to Reactivate Dormant Cells in the Retinahttps://modernod.com/news/researchers-found-a-way-to-reactivate-dormant-cells-in-the-retina/2481610/There's new hope for potentially restoring vision in patients suffering from degenerative retinal disease, thanks to work by researchers at Université de Montréal (UdeM). Published this week in Proceedings of the National Academy of Sciences, the research was
- Regeneron to Present New Data and Analyses of High-Dose Aflibercept at ARVO 2023https://modernod.com/news/regeneron-to-present-new-data-and-analyses-of-high-dose-aflibercept-at-arvo-2023/2481537/Regeneron Pharmaceuticals and its collaborator Bayer announced that aflibercept 8 mg and Eylea (aflibercept) Injection will be featured in 18 presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting from April 23-27. Among the presentations wi